Thu.Dec 05, 2024

article thumbnail

Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment

Pharmaceutical Technology

Dewpoint Therapeutics and MTPC have entered a strategic research partnership focusing on the development of TDP-43 small molecule c-mod.

article thumbnail

India takes centre-stage in clinical trials for HIV/AIDS drug

AuroBlog - Aurous Healthcare Clinical Trials blog

India has taken centre-stage in clinical trials for HIV/AIDS drug as there are several ongoing clinical trials in India focused on advancing HIV treatment. These trials are investigating new drug candidates, therapies, and approaches to manage HIV more effectively and potentially cure it.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

December 5, 2024: Nudge Pragmatic Trial Finds No Improvement in Adherence to Cardiovascular Medications

Rethinking Clinical Trials

Dr. Michael Ho and Dr. Sheana Bull, principal investigators for Nudge Text message–based reminders to patients who delayed refilling their cardiovascular medications did not improve medication adherence compared with usual care in the recently completed Nudge trial. The results of the study were published online ahead of print in JAMA. Nudge, an NIH Collaboratory Trial, was a randomized, pragmatic clinical trial embedded in 3 healthcare systems testing a variety of text messaging strategies to

Trials 157
article thumbnail

Protecting Your Muscle Mass Is Vital For Healthy Aging – Here’s Why

AuroBlog - Aurous Healthcare Clinical Trials blog

Skeletal muscle fibers (multinucleated cells) with their nerve connections. (Ed Reschke/Stone/Getty Images) We’d all like to live longer; at least, I would. But what about enjoying the time we have while we’re here and living healthier? Over the past century, human life expectancy has dramatically increased for a variety of reasons.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise

Bio Pharma Dive

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.

187
187
article thumbnail

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Pharmaceutical Technology

The FDA has granted accelerated approval to Merus’ Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers.

147
147

More Trending

article thumbnail

LEO Pharma’s eczema cream gains MHRA marketing authorisation

Pharmaceutical Technology

LEO Pharma has gained marketing authorisation from the MHRA for Anzupgo to treat chronic hand eczema (CHE) in Great Britain.

Marketing 147
article thumbnail

Nuvig pulls in $161M to make better immune drugs

Bio Pharma Dive

The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory conditions, starting with an antibody near Phase 2 testing.

Antibody 170
article thumbnail

FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC

Pharmaceutical Technology

The US FDA has approved AstraZeneca's Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.

article thumbnail

NICE endorses Neuraxpharm’s ublituximab for treating MS

Pharma Times

New antibody therapy shows promise in managing condition

Antibody 142
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Harnessing Marketing Networks in the Pharmaceutical Industry: Strategies for Success

Pharma Marketing Network

Table of Contents Sr# Headings 1 Introduction: The Power of Marketing Networks 2 What Are Marketing Networks? 3 The Importance of Marketing Networks in Pharma 4 Building Healthcare Professional (HCP) Networks 5 Patient Advocacy Groups: A Trusted Connection 6 Digital Marketing Networks in Pharma 7 Branded Campaigns and Marketing Networks 8 Overcoming Challenges in Marketing Networks 9 The Role of Data in Strengthening Networks 10 Future Trends in Marketing Networks 11 Practical Tips for Pharma Ma

article thumbnail

Teva’s Ajovy shows positive results in preventing pediatric migraines

Pharma Times

Phase 3 trial indicates significant efficacy and safety for children and adolescents

Trials 141
article thumbnail

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.

Trials 104
article thumbnail

Still no clear motive in UnitedHealth CEO killing

pharmaphorum

Investigations continue into the death of UnitedHealth chief executive Brian Thompson, who was shot and killed by an unknown assailant in New York

102
102
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.

Trials 96
article thumbnail

Mounjaro cleared for NHS use, but patients may have to wait

pharmaphorum

Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE

98
article thumbnail

AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer

Fierce Pharma

AstraZeneca has picked off another label expansion for cancer blockbuster Imfinzi as the FDA has blessed it for limited-stage small cell lung cancer.

96
article thumbnail

Novartis bid to block generic Entresto in US suffers setback

pharmaphorum

An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

98
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Novartis' latest attempt to fend off MSN's Entresto generic falls short on appeal

Fierce Pharma

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court. | The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching.

85
article thumbnail

Merus grabs first-in-class US approval for NRG1 cancer drug

pharmaphorum

Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer

article thumbnail

Amgen rolls out $1B investment to build new drug substance plant in NC's biopharma hotbed

Fierce Pharma

Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production footprint in North Carolina. | Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina. Together with Amgen’s existing facility in the town, the company’s investments in Holly Springs are slated to create a total of 370 new jobs.

Drugs 64
article thumbnail

Money vs mindset: How the NHS can make the most of extra investment

pharmaphorum

Discover how the NHS can optimise extra funding by balancing budget allocation with a focus on mindset and strategic choices to improve patient care and organisational efficiency.

92
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Learning from Your Mistakes: Keeping Sites from Repeatedly Tripping Over the Same Noncompliance Issues

ACRP blog

How can clinical trial sites decrease the most common noncompliance issues cited in regulatory inspections? It’s a big challenge to sites of all types, and one with major impacts on the safe, ethical, and efficient conduct of life-enhancing drug and device studies. Tackling this topic in a presentation on “ Detecting and Addressing the Quality Pitfalls at Study Sites ” at the ACRP 2025 conference next April in New Orleans, La., will be ACRP Fellows Jerry M.

article thumbnail

FDA clears AZ's Imfinzi for aggressive lung cancer

pharmaphorum

AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC)

article thumbnail

Policy and Population Health

Pharmaceutical Commerce

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?

52
article thumbnail

Proactive Planning to Navigate Clinical Research Staffing Trends in 2025 | Advanced Clinical

pharmaphorum

Explore proactive planning strategies to navigate upcoming staffing trends in clinical research by 2025 with Advanced Clinical. Stay ahead of the curve in the ever-evolving landscape of clinical research.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

The Advantages of New Medicare Rx Payment Plan

Pharmaceutical Commerce

While the program could be a good option for many, it's not a panacea.

52
article thumbnail

Welcome to the Bacteriophage Therapy Summit!

pharmaphorum

Welcome to the Bacteriophage Therapy Summit! Mike.

52
article thumbnail

Consequences of Non-Compliance

Pharmaceutical Commerce

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, comments on what the repercussions are for failing to comply with the DSCSA.

article thumbnail

Data-driven planning for the participant burden in clinical trials

pharmaphorum

Data-driven planning for the participant burden in clinical trials involves optimising trial design based on insights from past studies to minimise participant burden and enhance recruitment and retention. Learn more about the importance of data-driven planning in clinical trials.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud